Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | CNR1 | P21554 | 4/20 | 0.79 |
| ▸ | NPC1 | O15118 | 3/20 | 0.79 |
| ▸ | RAB9A | P51151 | 3/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.79 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | FPR2 | P25090 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | CA2 | P00918 | 4/20 | 0.70 |
| ▸ | CA12 | O43570 | 3/20 | 0.70 |
| ▸ | CA1 | P00915 | 3/20 | 0.70 |
| ▸ | CA9 | Q16790 | 3/20 | 0.70 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.70 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19472678 | 0.90 | FPR2 (0.69) | EPHX1KDM4ECNR1NPC1RAB9A | |
| SCHEMBL12196188 | 0.89 | EPHX1 (1.00) | EPHX1KDM4ECNR1NPC1RAB9A | |
| SCHEMBL4898196 | 0.89 | KMT2A (0.81) | EPHX1KDM4ECNR1NPC1RAB9A | |
| SCHEMBL4894746 | 0.89 | CNR1 (1.00) | EPHX1KDM4ECNR1NPC1RAB9A | |
| SCHEMBL11615935 | 0.89 | ROCK2 (0.79) | EPHX1KDM4ECNR1NPC1RAB9A | |
| SCHEMBL10192078 | 0.89 | ALDH1A1 (0.83) | EPHX1KDM4ECNR1NPC1RAB9A | |
| SCHEMBL5516178 | 0.89 | CNR1 (0.73) | EPHX1KDM4ECNR1NPC1RAB9A | |
| SCHEMBL4897395 | 0.89 | CNR1 (0.74) | EPHX1KDM4ECNR1NPC1RAB9A | |
| SCHEMBL27475656 | 0.89 | CNR1 (0.68) | EPHX1KDM4ECNR1NPC1RAB9A | |
| SCHEMBL16857481 | 0.89 | CNR1 (0.73) | EPHX1KDM4ECNR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227999-A1 | Heterogeneous Supported Catalytic Carbamate Process | MOLZAHN DAVID C | 2008-09-18 | — | — | US | claimed |
| EP-4465988-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | Calcimedica, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023141523-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | CALCIMEDICA, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20160124123-A1 | CELLULOSE ACYLATE FILM, POLARIZING PLATE, AND LIQUID CRYSTAL DISPLAY USING THE SAME | FUJIFILM CORPORATION (JP) | 2016-05-05 | — | — | US | disclosed |
| US-20130267712-A1 | AROMATIC KETONE SYNTHESIS WITH AMIDE REAGENTS AND RELATED REACTIONS | BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267712-A1 | AROMATIC KETONE SYNTHESIS WITH AMIDE REAGENTS AND RELATED REACTIONS | BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY (US) | 2013-10-10 | — | — | US | disclosed |
| US-20080227999-A1 | Heterogeneous Supported Catalytic Carbamate Process | MOLZAHN DAVID C | 2008-09-18 | — | — | US | disclosed |
| EP-1943214-A2 | HETEROGENEOUS SUPPORTED CATALYTIC CARBAMATE PROCESS | Dow Gloval Technologies Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007015852-A2 | HETEROGENEOUS SUPPORTED CATALYTIC CARBAMATE PROCESS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-4567287-A | Preparation of carbamates from organic carbonates and aromatic ureas | THE UPJOHN CO. (US) | 1986-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227999-A1 | Heterogeneous Supported Catalytic Carbamate Process | CPS1, CAT, CA7 | EPHX1 4546/4885KDM4E 126/4885CNR1 1757/4885 |
| US-20130267712-A1 | AROMATIC KETONE SYNTHESIS WITH AMIDE REAGENTS AND RELATED REACTIONS | NAAA, AADAC, NISCH | EPHX1 2340/4885KDM4E 835/4885CNR1 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.